We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

JPMorgan's bitter medicine

20 September 2006 By Robert Cyran

The 2004 buyout of the UK drugs group by a bankled consortium sparked controversy and nudged winner JPM out of private equity. Chilcott s upcoming float could result in the consortium nearly tripling its money. The associated returns will be sadly missed.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)